Tech Company M&A Transactions
AnorMED Acquisition
AnorMED was purchased by Genzyme. The deal became public on 11/8/2006. The transaction price was $584 million.
Transaction Overview
Company Name
Acquired By
Announced On
11/8/2006
Transaction Type
M&A
Amount
$584,000,000
M&A Terms
Genzyme initially bid $380 million for AnorMed but Cambridge, Mass.-based Millennium Pharmaceuticals Inc. (Nasdaq: MLNM) out bid it with a $515 million offer, forcing Genzyme to increase its bid to $584 million.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
20353 64th Ave. 200
Langley BC, V2Y 1N5
Canada
Langley BC, V2Y 1N5
Canada
Phone
Website
Email Address
Not Recorded
Overview
AnorMED Inc. was established by a team of seven scientists, most of whom worked together from 1985 as integral members of the biomedical research group of Johnson Matthey plc (JM), U.K. This group was dedicated to the discovery and preclinical development of metal-based pharmaceuticals.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Kenneth Galbraith
Browse more venture capital transactions:
Prev: 11/8/2006: AlterPoint venture capital transaction
Next: 11/8/2006: Solstice Neurosciences venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to document every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs